Latest Tarenflurbil Stories

2011-09-25 15:24:40

Ibuprofen, naproxen, and related non-steroidal anti-inflammatory drugs (NSAIDs) — the subjects of years of study — still have some secrets to reveal about how they work. Vanderbilt University investigators have discovered surprising new insights into the actions of NSAIDs. Their findings, reported Sept. 25 in Nature Chemical Biology, raise the possibility of developing a new class of inflammation- and pain-fighting medicines. NSAIDs block the activity of the cyclooxygenase...

2010-08-17 07:00:00

INDIANAPOLIS, Aug. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. The company's decision does not affect...

2009-12-16 00:16:33

Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a study in the December 16 issue of JAMA. A leading theory on the pathophysiology of Alzheimer disease (AD) is the overproduction of amyloid-ÃŽ²...

2008-10-03 12:00:05

Eli Lilly and Company has announced that it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease. Identity 2 is expected to enroll 1,100 patients, and includes a treatment period of approximately 21 months. An open-label extension will be available to all participants completing the study. In Identity 2, patients will be randomized to...

2008-09-18 09:00:11

By Lois M. Collins Deseret News Researchers at the University of Utah are looking for volunteers who have mild to moderate Alzheimer's disease to test a drug that may slow its associated decline. The compound they're studying acts on beta amyloids, proteins that tend to deposit in the brains of patients with Alzheimer's, according to Edward Zamrini, associate professor of neurology at the U. School of Medicine. He's also clinical trials director at the Center for Alzheimer's Care, Imaging...

2008-07-31 12:00:23

U.S. medical scientists say a drug commonly prescribed to treat immunodeficiencies has shown promise as a treatment for Alzheimer's disease. Researchers at NewYork-Presbyterian Hospital and the Weill Cornell Medical Center announced the nine-month interim results of an ongoing Phase II double-blind, placebo-controlled clinical trial of gammagard intravenous immunoglobulin, or IGIV. Those results show significantly better global outcomes, cognitive performance and daily functioning in...

2008-07-31 06:00:00

By Jeremy Manier, Chicago Tribune Jul. 31--Editor's note: Due to a production error, this story from Wednesday's newspaper did not run in full. This is the complete text. Hope is often scarce in research on Alzheimer's disease, but a study released Tuesday at a Chicago medical conference offered tentative hope for a new way of slowing elderly patients' mental decline. The preliminary study of 321 Alzheimer's patients from Singapore and Britain found that an old drug, previously used...

2008-07-30 16:34:03

An experimental Alzheimer's drug shows promise in halting progression of the disease through a new approach of dissolving the protein tangles that form in victims' brain. The results were announced Tuesday at a Chicago medical conference, and came as welcome news to an industry besieged with recent setbacks. The drug, called Rember, was developed by Singapore-based TauRx Therapeutics. But even if larger, more comprehensive tests prove Rember works, it would still be several years before the...

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.